decoded.report LIVE FROM SEC FILINGS
CASE FILE · OPENED JUST FOR YOU

ALLO

Allogene Therapeutics, Inc.
LAST CLOSE… Biological Products, (No Diagnostic Substances) SHARES +58.0% · 12M CASH ~5 MO
78
SEVERE
RISK INDEX
RED FLAGS 42 SHARE PRINTING 20 RUNWAY 14 YEARS-LONG PATTERN 2 = 78/100. WHY THIS NUMBER, PIECE BY PIECE.

THE READ 16 red-flag mentions across this year's filings, led by dilution and delisting / exchange risk, and 57 since 2001, so this is a long-running pattern; share count jumped 58% in a year (holders are being diluted fast); only about 5 months of cash at the current burn rate.

FLAGS DILUTION CASH WHAT CHANGED VERDICT INSIDERS OUTSIDE RECORDS
01

Red Flags

2025-09-06 → 2026-09-06

We read every document this company filed with the SEC this year and counted the classic danger phrases. Where wording can be misleading, we open the actual documents and separate real warnings from accounting boilerplate. Each hit links to the exact document.

Dilution (at the market offering) AT LEAST 12 REAL WARNINGS · 9 matching docS this year · 44 ALL TIME

An ATM lets the company print and sell new shares into the market any day it wants. Every print dilutes your slice.

EVIDENCE: [1] 424B5 FILED 2026-06-22 · [2] 8-K FILED 2026-03-12 · [3] 424B5 FILED 2026-04-13 · [4] 424B5 FILED 2026-04-15 · [5] S-3 FILED 2026-08-12

Reverse stock split 0 THIS YEAR · 4 ALL TIME

A reverse split shrinks the share count to lift the price above $1. Repeat reverse splits are the classic death-spiral signature.

Going concern doubt 0 THIS YEAR · 2 ALL TIME

Auditors flagged substantial doubt the company survives the next 12 months without new money.

Delisting / exchange risk 4 REAL WARNINGS · 4 matching docS this year · 7 ALL TIME

The exchange has threatened to kick the stock off. Delisting pressure usually ends in a reverse split or a fire-sale raise.

EVIDENCE: [1] 10-Q FILED 2026-05-13 · [2] 10-Q FILED 2025-11-06 · [3] 10-Q FILED 2026-08-12 · [4] 10-K FILED 2026-03-12

SOURCE: FULL-TEXT SEARCH OF THE COMPANY'S OFFICIAL SEC FILINGS. "REAL WARNINGS" = WE OPENED THE LINKED DOCUMENTS AND FILTERED PHRASES WRAPPED IN NEGATIONS, RESOLUTION LANGUAGE OR STANDARD CONTRACT TERMS. "AT LEAST" = MORE DOCUMENTS CARRY THE PHRASE THIS YEAR THAN WE COULD OPEN AND READ.

02

The Printing Press

How many shares exist, over time, exactly as the company reported in its own filings. In microcaps, a rising share count is how holders pay for everything: salaries, debts, and bad deals. Sudden collapses in the line are reverse splits, marked below.

121,482,671 shares · 2018-11-15 345,490,881 shares · 2026-08-10 LAST 12M: +58.0% AVG/YEAR SINCE 2018: +14.5%

SOURCE: THE COMPANY'S OWN REPORTED SHARE COUNTS ACROSS 32 FILINGS, STRAIGHT FROM SEC RECORDS

CHECKING OFFICIAL SPLIT RECORDS…

What this means for YOUR shares

Type how many shares you hold. The math is plain division on the company's own reported counts.

03

Cash Countdown

Cash in the bank against how fast the company burns it. When this hits zero, the next stop is usually a desperate raise at bad terms, and existing holders pay through dilution.

~5 MONTHS OF CASH AT THE CURRENT BURNBAR = SHARE OF A 24-MONTH WINDOW
5 MO
EST RUNWAY
cash ÷ monthly burn
$7.59M
MONTHLY BURN
operating cash deficit
$38.63M
CASH ON HAND
latest reported quarter
+27.4%
CASH CHANGE QoQ
latest two reported quarters
2024·92024·122025·32025·62025·92025·122026·32026·6
CASH OVER TIME, LAST 8 REPORTED QUARTERS $51.24M → $38.63M TREND: -24.6%

RUNWAY = CASH ON HAND ÷ MONTHLY CASH BURN. SIMPLE ARITHMETIC ON THE COMPANY'S OWN REPORTED NUMBERS, NOT A PROJECTION.

04

What the Newest Filing Changed

The latest filings, translated into holder impact. Every number cites its form, date and SEC link.

Shares outstanding +0.1%

Shares outstanding rose 345.15M to 345.49M (+0.1%) between 10-Q 2026-05-11 and 10-Q 2026-08-10.

NOW: 345,490,881 as of 2026-08-10 (10-Q, filed 2026-08-12)

WAS: 345,154,561 as of 2026-05-11 (10-Q, filed 2026-05-13)

Cash and equivalents +27.4%

Cash and equivalents rose $30.31M to $38.63M ($8.32M, +27.4%) between 10-Q 2026-03-31 and 10-Q 2026-06-30.

NOW: $38.63M as of 2026-06-30 (10-Q, filed 2026-08-12)

WAS: $30.31M as of 2026-03-31 (10-Q, filed 2026-05-13)

Total assets +38.9%

Total assets rose to $550.09M (from $395.96M, +38.9%) between 10-Q 2026-03-31 and 10-Q 2026-06-30.

NOW: $550.09M as of 2026-06-30 (10-Q, filed 2026-08-12)

WAS: $395.96M as of 2026-03-31 (10-Q, filed 2026-05-13)

Total liabilities -2.7%

Total liabilities fell to $113.92M (from $117.08M, -2.7%) between 10-Q 2026-03-31 and 10-Q 2026-06-30.

NOW: $113.92M as of 2026-06-30 (10-Q, filed 2026-08-12)

WAS: $117.08M as of 2026-03-31 (10-Q, filed 2026-05-13)

Revenue +0.0%

Revenue held flat at $0 to $4.64M (+0.0%) between the period ended 2025-09-30 and the period ended 2026-06-30 (10-Q).

NOW: $4.64M as of 2026-06-30 (10-Q, filed 2026-08-12)

WAS: $0 as of 2025-09-30 (10-Q, filed 2025-11-06)

Cash burn / runway

Monthly operating cash deficit ~$7.59M ($-44.91M over the period ended 2026-06-30 in 10-Q). Against $38.63M cash is roughly 0.4 years of runway (5 months).

NOW: $-44.91M as of 2026-06-30 (10-Q, filed 2026-08-12)

!

Critical 8-K Ledger

OFFICIAL NOTICES · 24 MO

When something material happens, the company itself must announce it in an 8-K under the SEC's numbered item system. These are those announcements, newest first: bankruptcy papers, exchange delisting warnings, auditor changes, financials pulled back. Read straight from the SEC filing index, no interpretation layer.

2026-09-02 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2026-05-28 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗
2025-01-29 ITEM 5.02 · OFFICER / DIRECTOR EXIT FILING ↗

SOURCE: THE ITEM NUMBERS THE COMPANY ITSELF PUT ON EACH 8-K IN THE SEC'S FILING INDEX. HOVER A STAMP FOR WHAT THAT ITEM MEANS FOR YOUR SHARES. OFFICIAL NOTICES INSIDE THE LAST 12 MONTHS ALSO FEED THE RISK INDEX ABOVE (CAPPED AT 15 POINTS).

2023·92024·32024·62024·92025·32025·62025·92026·6
QUARTERLY REVENUE, LAST 8 QUARTERS $22K → $4.64M TREND: +20990.9%

EACH BAR IS ONE REPORTED QUARTER. GREEN = MOST RECENT QUARTER GREW VS THE ONE BEFORE.

!

Breaking Filing

8-K · 2026-09-02

An 8-K is the "something happened right now" filing. Here is what this one says, in the company's own words.

Item 5.02

(b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.

READ THE ORIGINAL FILING

05

The Verdict

AVOID · HIGH CONFIDENCE

A rules-based reading of the cited filing facts: a range with reasons, never a prediction.

AVOID
SCREENING VERDICT
HIGH confidence
$0.6312-$0.6312
FAIR VALUE BRACKET
book equity of $1.26/share at 0.5-1.0x
$1.97
LAST CLOSE
non-realtime

HOW THE BRACKET IS BUILT: BOOK EQUITY OF $1.26/SHARE AT 0.5-1.0X · MULTIPLES STRIPPED: UNDER A YEAR OF CASH AT THE CURRENT BURN, SO THE BRACKET CAPS AT WIND-DOWN CASH · CASH FLOOR: $0.1118/SHARE IN A WIND-DOWN.

BASIS FOR

+1

Share count is stable-ish (+0.1% change between the last two reported quarters).

+2

Fair-value range anchored to cited facts: $0.6312 to $0.6312 per share.

AGAINST

−1

Cash of $38,626,000 funds under half a year of operating burn, a hard going-concern pressure without fresh capital.

−2

The filings do not publish comparable revenue figures for two consecutive periods, so the revenue trend could not be measured.

METHOD: DETERMINISTIC RULES OVER CITED SEC FILING FACTS: SHARE-COUNT CHANGE BETWEEN THE LAST TWO REPORTED QUARTERS (DILUTION), CASH-TO-BURN RUNWAY FROM THE MOST RECENT OPERATING CASH FLOW, PERIOD-OVER-PERIOD REVENUE GROWTH, AND A FAIR-VALUE RANGE ANCHORED TO CASH PER SHARE VS PRICE. THRESHOLDS ARE TUNABLE IN APP/VERDICT_ENGINE.PY. NOT A PREDICTION.

06

Insider Paper Trail

NET SELLING

Every time an officer, director or big owner trades shares, the law makes them file a Form 4 within two business days. We read the actual filings: who traded, what kind of trade, how big, at what price.

0
OPEN-MARKET BUYS
nobody is buying with their own cash
1
OPEN-MARKET SELLS
29,697 shares · ~$63K cashed out
11
GRANTS / AWARDS
1,422,920 new shares/options handed out: future dilution
2026-032026-042026-052026-062026-072026-08
ABOVE THE LINE: CASH BUYS BELOW THE LINE: CASH SELLS 6 MO: +$0 / -$63K

EACH MONTH SHOWS OPEN-MARKET DOLLAR FLOW PARSED FROM FORM 4 FILINGS. GRANTS AND OPTION PAPER ARE EXCLUDED: THIS IS REAL MONEY IN AND OUT.

DATEWHOACTION
2026-08-21 Douglas Earl Martin SVP, GENERAL COUNSEL OPEN-MARKET SELL 29,697 @ $2.12
2026-07-01 Roberts Zachary PRESIDENT AND CEO GRANT/AWARD 134,530 OPTIONS/DERIVATIVE
2026-07-01 Roberts Zachary PRESIDENT AND CEO GRANT/AWARD 476,190 OPTIONS/DERIVATIVE
2026-06-18 Kazam Joshua A DIRECTOR OPTION EXERCISE 47,700
2026-06-18 Kazam Joshua A DIRECTOR OPTION EXERCISE 47,700 OPTIONS/DERIVATIVE
2026-06-18 Kazam Joshua A DIRECTOR GRANT/AWARD 95,400 OPTIONS/DERIVATIVE
2026-06-18 MESSEMER DEBORAH M. DIRECTOR GRANT/AWARD 95,400 OPTIONS/DERIVATIVE
2026-06-18 Mayo Stephen DIRECTOR GRANT/AWARD 144,400 OPTIONS/DERIVATIVE
2026-06-18 SATO VICKI L DIRECTOR GRANT/AWARD 95,400 OPTIONS/DERIVATIVE
2026-06-18 WITTE OWEN N. DIRECTOR GRANT/AWARD 95,400 OPTIONS/DERIVATIVE
2026-06-18 Humer Franz B DIRECTOR GRANT/AWARD 95,400 OPTIONS/DERIVATIVE
2026-06-18 Barrett Elizabeth A. DIRECTOR GRANT/AWARD 95,400 OPTIONS/DERIVATIVE

PEOPLE WITH THE BEST INFORMATION ABOUT THIS COMPANY ARE SELLING MORE THAN THEY BUY. NOT PROOF OF ANYTHING: EXECUTIVES SELL FOR MANY REASONS. BUT AT MICROCAP SCALE, IT RARELY SMELLS GOOD. "10B5-1 PLAN" MEANS THE TRADE WAS SCHEDULED UNDER A PRE-SET TRADING PLAN, DISCLOSED IN THE FILING'S OWN FOOTNOTES: PRE-PLANNED SALES CARRY LESS SIGNAL THAN SPUR-OF-THE-MOMENT ONES. SOURCE: FORM 4 FILINGS, PARSED FROM THE SEC'S OWN XML, LAST 9 FILINGS.

07

Filing Timeline

The company's most recent SEC paperwork, newest first.

8-K 2026-09-02 0001193125-26-379423
4 2026-08-25 0001628280-26-058920
144 2026-08-21 0001737287-26-000023
EFFECT 2026-08-20 9999999995-26-002725
SCHEDULE 13G/A 2026-08-14 0001231919-26-000912
S-3 2026-08-12 0001628280-26-056232

SOURCE: THE COMPANY'S SEC FILING INDEX

08

Outside the Filings

Public records that most investors never check, cross-checked against what the company claims. This is where shells slip up.

allogene.com
WEB ADDRESS ON RECORD
registered 2002-12-02 · via GoDaddy.com, LLC
23.8 YRS OLD
DOMAIN AGE
old and consistent with an operating company: a good sign
3
OFFICIAL OFFERING DOCS · 12M
last one 2026-06-22: shares were actually sold to the market
1
SHELF REGISTRATIONS · 12M
paperwork filed to allow future share sales: future dilution waiting
0
BIG-OWNER TAKEOVER FILINGS · 12M
no outside investor has crossed the 5% disclosure line this year
PUBLIC FLOAT
shares actually tradable, vs held by insiders and big owners
SOLD SHORT
FINRA short interest: how many shares are bets against this company, and how many days of trading it would take to cover
CLEAR
US SANCTIONS SCREEN
company name checked against the official US sanctions list (19292 entries)
LEGAL IDENTITY (LEI)
every company that trades securities must carry a global legal identifier: status, parent chain and subsidiaries from the official registry
INSTITUTIONAL HOLDERS · 13F
quarterly institutional holdings filings scanned for this exact company name: which funds still report holding shares, from their own filings
SITE HISTORY
how long the company's website has been around, per the public web archive
CERT RECORD
public certificate logs date the company's web infrastructure: old and boring is good, brand-new is a tell
REGISTRANT HISTORY
old snapshots of public WHOIS pages: has the registered owner of this address changed hands
HOSTING + MAIL RECORDS
public DNS records: where the address is pointed and whether it can even receive mail
Web address registration expires soon

Cross-referenced from public domain registration records, not from anything the company says about itself.

SOURCES: PUBLIC DOMAIN REGISTRATION RECORDS (FOUND IN THE COMPANY'S OWN FILING SIGNATURES) · THE COMPANY'S SEC FILING INDEX · OFFICIAL US SANCTIONS LIST · QUARTERLY 13F FILINGS VIA EDGAR FULL-TEXT SEARCH · LEGAL-IDENTITY, SITE-HISTORY, CERTIFICATE, REGISTRANT-HISTORY AND DNS SLOTS STREAM IN FROM FREE PUBLIC REGISTRIES WITHOUT BLOCKING THIS PAGE.

Others Under The Scanner

Real visitors who opened this case file also checked these tickers. Derived only from on-site search and watchlist activity of the last 90 days: no tracking, no cookies.

09

Company Record

Legal nameAllogene Therapeutics, Inc.
Fiscal year end1231
HQ210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Last periodic report2026-08-12 (10-Q, 26d ago)
Shares outstanding345,490,881 as of 2026-08-10 (10-Q)

SOURCE: THE COMPANY'S SEC FILING INDEX

Next time ALLO files something scary, know within minutes.

One Telegram message per material filing: dilution, going concern, delisting, insider dumps. No account, no email. Every line cites its SEC source. Leave anytime with /unwatch.

WATCH ALLO ON TELEGRAM →
+

Decode Another Ticker